- Home
- NEA vs MLTX Comparison
NEA vs MLTX Comparison
Compare NEA & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEA
- MLTX
- Stock Information
- Founded
- NEA 2002
- MLTX 2021
- Country
- NEA United States
- MLTX Switzerland
- Employees
- NEA N/A
- MLTX N/A
- Industry
- NEA Finance/Investors Services
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- NEA Finance
- MLTX Health Care
- Exchange
- NEA Nasdaq
- MLTX Nasdaq
- Market Cap
- NEA 3.3B
- MLTX 2.8B
- IPO Year
- NEA N/A
- MLTX N/A
- Fundamental
- Price
- NEA $10.87
- MLTX $55.89
- Analyst Decision
- NEA
- MLTX Strong Buy
- Analyst Count
- NEA 0
- MLTX 7
- Target Price
- NEA N/A
- MLTX $74.83
- AVG Volume (30 Days)
- NEA 803.4K
- MLTX 463.4K
- Earning Date
- NEA 01-01-0001
- MLTX 08-05-2025
- Dividend Yield
- NEA 4.23%
- MLTX N/A
- EPS Growth
- NEA N/A
- MLTX N/A
- EPS
- NEA N/A
- MLTX N/A
- Revenue
- NEA N/A
- MLTX N/A
- Revenue This Year
- NEA N/A
- MLTX N/A
- Revenue Next Year
- NEA N/A
- MLTX N/A
- P/E Ratio
- NEA N/A
- MLTX N/A
- Revenue Growth
- NEA N/A
- MLTX N/A
- 52 Week Low
- NEA $9.20
- MLTX $31.42
- 52 Week High
- NEA $11.37
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- NEA 51.73
- MLTX 62.07
- Support Level
- NEA $10.77
- MLTX $52.02
- Resistance Level
- NEA $11.03
- MLTX $55.81
- Average True Range (ATR)
- NEA 0.06
- MLTX 1.83
- MACD
- NEA -0.01
- MLTX -0.09
- Stochastic Oscillator
- NEA 38.46
- MLTX 95.44
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.